Back to Blog
Scientists at Adimab in New Hampshire isolated several antibodies from the memory B cells (immune cells) of a person, who had survived a SARS infection in 2003. The researchers engineered these antibodies and created a new ADG-2, a new antibody that was particularly effective at disabling SARS-CoV-2 and several related coronaviruses in lab experiments. ADG-2 was also effective in treating SARS-and COVID-19 infections in mice.
What makes ADG-2 antibody different than others? It recognizes a highly conserved epitope on the surface of these viruses, which authors compare to the Achilles’ heel, making ADG-2 a promising therapy candidate that more effective and broad range than other antibodies.